行情

XENE

XENE

Xenon Pharms
NASDAQ

实时行情|Nasdaq Last Sale

9.28
+0.02
+0.22%
交易中 12:12 09/18 EDT
开盘
9.13
昨收
9.26
最高
9.28
最低
9.17
成交量
3,171
成交额
--
52周最高
13.85
52周最低
5.41
市值
2.39亿
市盈率(TTM)
-5.3050
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

XENE 新闻

  • 黄铮的第二封股东信
  • 新浪财经-自媒体综合.33分钟前
  • 联邦快递股价暴跌超14% 华尔街投行纷纷下调其评级
  • 新浪美股.49分钟前
  • 美国银行称美联储已达到储备稀缺状态 将作出回应
  • 新浪美股.1小时前
  • 摩根士丹利:美联储料将宣布出台永久性公开市场操作
  • 新浪美股.1小时前

更多

所属板块

生物技术和医学研究
-1.04%
制药与医学研究
-0.23%

热门股票

名称
价格
涨跌幅

XENE 简况

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.
展开

Webull提供Xenon Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。